Result For Quarter ended Dec 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Caprolactam Chemicals reported its Q3 FY26 (quarter ended Dec 2025) results on Feb 13, 2026. Revenue from operations rose to ₹256.31 lakhs, up from ₹229.38 lakhs in Q3 FY25 (YoY) and ₹236.27 lakhs in Q2 FY26 (QoQ). The company swung to a profit after tax of ₹43.55 lakhs (EPS ₹0.95), compared to a loss of ₹3.47 lakhs in Q3 FY25 and a profit of ₹12.56 lakhs in the previous quarter. For the nine months ended Dec 2025, revenue jumped to ₹749.05 lakhs (vs ₹513.10 lakhs in 9M FY25), with PAT of ₹92.32 lakhs reversing a loss of ₹25.81 lakhs in the prior-year period. Operating profitability improved sharply, with total expenses falling as a share of income. The board also approved revisions in remuneration for the MD and CFO, and new related-party transactions including property leasing and consultancy fees.
A clear turnaround story — the company has moved from losses in FY25 and Q3 FY25 to consistent profits in FY26, with strong revenue growth and margin expansion. Positive for shareholders, though the small scale of operations and related-party transactions worth noting.